---
layout: post
title: "AstraZeneca Pharmaceuticals LP; Withdrawal of Approval of New Drug Application for LYNPARZA (Olaparib) Capsules"
date: 2026-02-05 19:08:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-06298
original_published: 2024-03-26 00:00:00 +0000
significance: 8.00
---

# AstraZeneca Pharmaceuticals LP; Withdrawal of Approval of New Drug Application for LYNPARZA (Olaparib) Capsules

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 26, 2024 00:00 UTC
**Document Number:** 2024-06298

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for LYNPARZA (olaparib) Capsules, 50 milligrams (mg) held by AstraZeneca Pharmaceuticals LP (AZ), 1800 Concord Pike, Wilmington, DE 19803. AZ has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/26/2024-06298/astrazeneca-pharmaceuticals-lp-withdrawal-of-approval-of-new-drug-application-for-lynparza-olaparib)
- API: https://www.federalregister.gov/api/v1/documents/2024-06298

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
